What question did this study set out to answer?

This study aims to assess the cardiac safety of pegylated liposomal doxorubicin using endomyocardial biopsies in patients with advanced malignancies.

January 1, 2004Cancer Investigation

Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies

View Full Paper

Ask AI

Bookmark

Why the study?

Does pegylated liposomal doxorubicin prevent severe cardiotoxicity in patients with advanced malignancies receiving high cumulative anthracycline doses?

Population

8 patients with advanced malignancies receiving doxorubicin-equivalent doses >= 550 mg/m2 or >= 400 mg/m2…

Design

Case_series

Authors

AGAlberto GabizónHebrew University of Jerusalem OLOlga LyassCedars-Sinai Medical Center GBGerald J. BerryHeart Failure & Transplant

Discussion

Member takes

Implication

Pegylated liposomal doxorubicin may limit cardiotoxicity at high doses; single case report leaves open need for prospective validation.

Key Points

This study aims to assess the cardiac safety of pegylated liposomal doxorubicin using endomyocardial biopsies in patients with advanced malignancies.
Prospective study involving eight patients with advanced malignancies.
Endomyocardial biopsies were performed to evaluate cardiac effects after receiving pegylated liposomal doxorubicin.
Patients received doses over 550 mg/m2 of doxorubicin-equivalent or 400 mg/m2 of pegylated liposomal doxorubicin.
Median biopsy score was 0.75 (range, 0-1.5) after a median dose of 707.5 mg/m2 of pegylated liposomal doxorubicin.
Total anthracycline exposure was 908.5 mg/m2, including pegylated liposomal doxorubicin.
Results indicate minimized doxorubicin-related cardiotoxicity at doses above recommended lifetime limits.

Structured PICO

Does pegylated liposomal doxorubicin prevent severe cardiotoxicity in patients with advanced malignancies receiving high cumulative anthracycline doses?

Population

8 patients with advanced malignancies receiving doxorubicin-equivalent doses >= 550 mg/m2 (including pegylated liposomal doxorubicin) or >= 400 mg/m2 pegylated liposomal doxorubicin alone

Intervention

Pegylated liposomal doxorubicin

Outcome

Endomyocardial biopsy score (Billingham scale)safety

Pegylated liposomal doxorubicin minimizes doxorubicin-related cardiotoxicity, even at doses exceeding the recommended lifetime cumulative conventional dose.

Cite This Study

Gabizón et al. (2004) studied this question.

synapsesocial.com/papers/6a2096aebdfec2d08e8a3369 https://doi.org/10.1081/cnv-200032899

View Full Paper

Ask AI

Bookmark

Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil®/Caelyx®) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider